WellSpring BioCapital Partners is prepping 12 exchange-traded funds that will invest in companies invested in, producing or supporting cures for certain types of diseases. The firm partnered with the Ferghana Partners Group to help develop the indexes and the funds.
Sam Katz, ceo of WellSpring, said the timing of the offerings is related to the anticipated ongoing need of healthcare by the aging Baby Boomer population, in addition to the expectation that traditional cures will eventually be edged out by updated healthcare technology.
The Ferghana-WellSpring ETFs will track companies invested in health care diagnostics, respiratory and pulmonary diseases, various cancers, infectious diseases and cardiology, among others. While the funds will access relatively narrow areas, Katz said the ETFs provide more diversity than most investing in healthcare because mid- and small-cap securities will also be included.
A filing at the Securities and Exchange Commission didn’t detail expenses for the series. The ETFs, which will trade on the American Stock Exchange, are expected to be available by the end of the year.